Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Nickase fidelity drives EvolvR-mediated diversification in mammalian cells.
Hurtado JE et al.
Nature Communications, 2025
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Rustgi N et al.
The Oncologist, 2024
Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S et al.
Molecular Cancer Therapeutics, 2023
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
Poddutoori R et al.
Journal of Medicinal Chemistry, 2022
Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y et al.
Nature, 2021
Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation.
Hegedüs L et al.
Cancers, 2021
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.
Gao Y et al.
Cancer Discovery, 2019
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Yao Z et al.
Nature Medicine, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM et al.
Molecular Cancer Research : Mcr, 2017
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Oddo D et al.
Cancer Research, 2016
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ et al.
Cancer Discovery, 2013
ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G et al.
Molecular Cancer Therapeutics, 2012
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2009